Who to call at InnoCare Pharma, and when
Fundz watches for the moments InnoCare Pharma starts buying, and tells you who to reach.
- An alert the day InnoCare Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at InnoCare Pharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at InnoCare Pharma. With Fundz connected, it knows.
InnoCare and KeyMed Announce License Agreement with Prolium for ICP-B02 Bispecific Antibody
Contract Type
agreement
Description
InnoCare Pharma and KeyMed Biosciences have jointly entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody. The agreement includes upfront and near-term payments, other payments subject to milestones, and a minority equity stake in Prolium, as well as tiered royalties on future net sales.
Quick answer
InnoCare and KeyMed Announce License Agreement with Prolium for ICP-B02 Bispecific Antibody (January 20, 2025). InnoCare Pharma is based in Beijing, Beijing, China.
- What agreement did InnoCare Pharma announce on January 20, 2025?
- InnoCare Pharma and KeyMed Biosciences have jointly entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody. The agreement includes upfront and near-term payments, other payments subject to milestones, and a minority equity stake in Prolium, as well as tiered royalties on future net sales.
- What does InnoCare Pharma do?
- InnoCare Pharma is a leading biopharmaceutical company that focuses on the treatment of cancer and autoimmune diseases.
- Where is InnoCare Pharma based?
- InnoCare Pharma is based in Beijing, Beijing, China.
Source: Fundz verified event record.
Related People
InnoCare Pharma signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.